IL-17 receptor like molecules and uses thereof
The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of:
(a) the nucleotide sequence comprising nucleotides 50 through 1729 of SEQ ID NO: 4;
(b) the nucleotide sequence comprising nucleotides 50 through 1099 of SEQ ID NO: 4;
(c) the nucleotide sequence comprising nucleotides 89 through 1099 of SEQ ID NO: 4;
(d) the nucleotide sequence encoding the polypeptide comprising amino acids 1 through 560 of SEQ ID NO: 5;
(e) the nucleotide sequence encoding the polypeptide comprising amino acids 1 through 350 of SEQ ID NO: 5;
(f) the nucleotide sequence encoding the polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5;
(g) the nucleotide sequence encoding the polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17; and
(h) the nucleotide sequence fully complementary to any of (a)–(g).
2. A vector comprising the nucleic acid molecule of claim 1 .
3. An isolated host cell comprising the nucleic acid molecule of claim 1 .
4. An isolated host cell comprising the nucleic acid molecule of claim 1 operatively linked to regulatory sequence other than the promoter for a native IL-17 receptor like polypeptide.
5. The host cell of claim 3 that is a eukaryotic cell.
6. The host cell of claim 3 that is a prokaryotic cell.
7. A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 3 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.
8. A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 4 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.
9. A composition comprising the nucleic acid molecule of claim 1 and a pharmaceutically acceptable formulation agent.
10. The composition the of claim 9 , wherein said nucleic acid molecule is contained in a viral vector.
11. A viral vector comprising the nucleic acid molecules of claim 1 .
12. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes a polypeptide that induces inflammation.
13. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid molecule encodes a polypeptide that induces myelopiesis.
14. An isolated host cell modified by transformation or transfection with a regulatory nucleic acid, wherein said regulatory nucleic acid is operatively linked to the nucleic acid comprising the nucleotide of SEQ ID NO:4.
15. The host cell of claim 14 wherein the regulatory nucleic acid sequence is a promoter.
16. The host cell of claim 14 wherein the regulatory nucleic acid is a transcription factor.
17. A process of producing an IL-17 receptor like polypeptide comprising culturing the host cell of claim 14 under suitable conditions to express the polypeptide, and optionally isolating the polypeptide from the culture.
18. The process of any one of claims 7 , 8 and 17 wherein the nucleic acid molecule comprises promoter DNA other than the promoter DNA for the native IL-17 receptor like polypeptide operatively linked to the DNA encoding the IL-17 receptor like polypeptide.
19. A diagnostic reagent comprising a detectably labeled polynucleotide, wherein the polynucleotide encodes a polypeptide comprising the amino acid sequence selected from the group consisting of:
(a) amino acids 1 through 560 of SEQ ID NO: 5,
(b) amino acids 1 through 350 of SEQ ID NO: 5, and
(c) amino acids 14 through 350 of SEQ ID NO: 5.
20. The diagnostic reagent of claim 19 , wherein said labeled polynucleotide is a first-strand cDNA.
21. An isolated nucleic acid molecule comprising the nucleotide sequence of the cDNA clone contained in ATCC deposit number PTA-3176.
22. An isolated nucleic acid molecule comprising a nucleotide sequence, wherein the nucleotide sequence encodes a polypeptide comprising the extracellular domain of the amino acid sequence encoded by the cDNA clone contained in ATCC deposit number PTA-3177.
23. An isolated nucleic acid molecule comprising the nucleotide sequence of the cDNA clone contained in ATCC deposit number PTA-3178.
24. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide having an amino acid sequence that is at least 90 percent identical to amino acids 14 through 350 of SEQ ID NO: 5, wherein the polypeptide binds IL-17.
25. The isolated nucleic acid molecule comprising a nucleotide sequence encoding the polypeptide comprising amino acids 14 through 350 of SEQ ID NO: 5.
26. An isolated nucleic acid molecule comprising the nucleotide sequence comprising nucleotides 89 through 1099 of SEQ ID NO: 4.